Menopause as a Metabolic Event: What the SWAN Cohort Shows About Insulin Resistance and Fat Redistribution

The menopause transition behaves like a distinct metabolic event, not simply a slice of ordinary aging. In the Study of Women's Health Across the Nation (SWAN), a large multiethnic longitudinal cohort, insulin resistance rises and body fat migrates toward the abdomen during a narrow window around the final menstrual period, and these shifts track with falling estradiol rather than with the calendar. The changes are measurable, time-locked, and consequential for cardiometabolic risk, which is why understanding the biology matters more than treating midlife weight change as an inevitability.

Why the transition is a metabolic inflection, not a slow drift

For years, midlife metabolic change in women was folded into "getting older." SWAN, which has followed a diverse group of women for more than two decades, allowed researchers to separate the two by anchoring measurements to each woman's final menstrual period (FMP) rather than to her birthday. When the data are aligned this way, a pattern emerges that chronological age alone does not explain: several metabolic and body-composition variables change their slope around the FMP, then settle again afterward. That inflection is the signature of a hormonal event, not a steady drift.

This distinction is not academic. If the driver were purely aging, the trajectory would be roughly linear across midlife. Instead, the acceleration clusters in the perimenopausal window, which reframes how the change should be interpreted and monitored.

Fat redistribution: the SWAN body-composition trajectory

Greendale and colleagues used SWAN data to map body composition across an eighteen-year span, from roughly nine years before to ten years after the FMP, published in JCI Insight in 2019. Their central finding is easy to miss on a bathroom scale. The rate of fat gain roughly doubled beginning about two years before the FMP, while lean mass declined over the same interval. Both trajectories flattened within roughly two years after the FMP.

Body weight, by contrast, rose more or less linearly across the whole period, with no abrupt jump at menopause. The reason is arithmetic: accelerating fat gain and simultaneous lean loss partly offset each other, so total weight can look stable even as the composition beneath it shifts toward more fat and less muscle. A woman whose weight barely moves may still be undergoing a meaningful metabolic reorganization. The SWAN authors also documented that the pattern varied by race and ethnicity, a reminder that population averages do not map neatly onto any single person.

Visceral fat and the vascular signal

Where fat goes matters as much as how much accumulates. The SWAN Heart Study (Samargandy, Matthews, and colleagues, published in Menopause in 2021) measured abdominal visceral adipose tissue (VAT), the metabolically active fat packed around the organs, across the transition. VAT accumulation accelerated sharply in the roughly two years before the FMP, on the order of several percent per year, with comparatively little change earlier. When the analysis accounted for estradiol levels, that pre-FMP inflection was attenuated, which is consistent with declining estrogen contributing to the redistribution.

The study went further and linked this menopause-related VAT gain to greater internal carotid artery wall thickness, an early marker of atherosclerosis, after adjustment for traditional risk factors. In other words, the central fat that gathers during the transition is not cosmetic. It carries a measurable vascular signal at a stage when the process is still subclinical.

Insulin resistance across the transition

Visceral fat and insulin resistance travel together. Across SWAN analyses, insulin resistance worsened during the transition in a way that was not fully accounted for by age or by weight gain, pointing toward the hormonal shift itself as a contributor. Related SWAN work has examined how liver fat and sex hormone binding globulin relate to insulin resistance in midlife women, underscoring that the picture is a network of adipose tissue, hepatic metabolism, and sex-steroid biology rather than a single lever.

The practical translation is that a woman entering perimenopause with normal glucose handling may see it deteriorate over the transition, and that this can happen without a dramatic change in the number on the scale. This is a reason to interpret midlife metabolic markers in the context of menopausal stage.

What this does and does not tell us about hormone therapy

It is tempting to move directly from "estrogen decline drives fat redistribution" to a conclusion about treatment. The evidence does not support that leap, and this article is educational and not medical advice. Observational cohorts such as SWAN describe what happens to populations of women over time; they do not establish that a given intervention will produce a specific outcome for an individual.

On the policy side, in 2025 the U.S. Food and Drug Administration moved to change the labeling of menopausal hormone therapy products, advising sponsors to remove boxed-warning references to cardiovascular disease, breast cancer, and probable dementia, while retaining the boxed warning for endometrial cancer tied to systemic estrogen-alone therapy in women with a uterus. Read carefully, this is a change to what the label legally states and how benefit and risk are framed on it. It is not a recommendation, an endorsement, or a safety all-clear, and it does not tell any individual whether hormone therapy is appropriate for her. Whether to use menopausal hormone therapy remains a decision to be made with a clinician who knows the full clinical picture. The value of SWAN here is mechanistic: it clarifies why the metabolic terrain shifts, which helps women and clinicians ask sharper questions.

The takeaway

Aligning the data to the final menstrual period turns a vague story about midlife weight into a specific one. Fat accumulation accelerates and lean mass falls in the couple of years around the FMP, visceral fat rises in step with declining estradiol and tracks with early vascular change, and insulin resistance worsens beyond what aging alone predicts. Recognizing the transition as a metabolic event, with a beginning and an end, is what makes monitoring and individualized conversations possible.